216 related articles for article (PubMed ID: 17303473)
41. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
42. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Morsing P
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S248-54. PubMed ID: 9892173
[TBL] [Abstract][Full Text] [Related]
43. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
44. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Azizi M; Bissery A; Lamarre-Cliche M; Ménard J
Hypertension; 2004 Apr; 43(4):785-90. PubMed ID: 15023936
[TBL] [Abstract][Full Text] [Related]
45. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Ishii M
Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
[TBL] [Abstract][Full Text] [Related]
47. Hypertension after kidney transplantation: still a SECRET?
Lopau K; Wanner C
Nephrol Dial Transplant; 2010 Mar; 25(3):664-5. PubMed ID: 20042402
[No Abstract] [Full Text] [Related]
48. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers.
Belz GG; Fuchs B; Malerczyk C; Magin SG; Roll S; Mutschler E
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S45-7. PubMed ID: 9331006
[No Abstract] [Full Text] [Related]
49. Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
Kappert K; Tsuprykov O; Kaufmann J; Fritzsche J; Ott I; Goebel M; Bähr IN; Hässle PL; Gust R; Fleck E; Unger T; Stawowy P; Kintscher U
Hypertension; 2009 Oct; 54(4):738-43. PubMed ID: 19687349
[TBL] [Abstract][Full Text] [Related]
50. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Bauer JH; Reams GP
Arch Intern Med; 1995 Jul; 155(13):1361-8. PubMed ID: 7794084
[TBL] [Abstract][Full Text] [Related]
51. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
52. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
[TBL] [Abstract][Full Text] [Related]
53. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
54. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Janke J; Schupp M; Engeli S; Gorzelniak K; Boschmann M; Sauma L; Nystrom FH; Jordan J; Luft FC; Sharma AM
J Hypertens; 2006 Sep; 24(9):1809-16. PubMed ID: 16915030
[TBL] [Abstract][Full Text] [Related]
55. [Development of combined drugs (ARB and diuretics)].
Arakawa K
Nihon Rinsho; 2004 Mar; 62 Suppl 3():662-5. PubMed ID: 15171452
[No Abstract] [Full Text] [Related]
56. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Toblli JE; Muñoz MC; Cao G; Mella J; Pereyra L; Mastai R
Obesity (Silver Spring); 2008 Apr; 16(4):770-6. PubMed ID: 18239590
[TBL] [Abstract][Full Text] [Related]
57. [Nonpeptide angiotensin II-receptor antagonists].
Inada Y; Wada T; Shibouta Y; Nishikawa K
Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):217-28. PubMed ID: 7959414
[TBL] [Abstract][Full Text] [Related]
58. Angiotensin receptor blockers: new considerations in their mechanism of action.
Sica DA
J Clin Hypertens (Greenwich); 2006 May; 8(5):381-5. PubMed ID: 16687949
[TBL] [Abstract][Full Text] [Related]
59. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.
Murugesan N; Gu Z; Fadnis L; Tellew JE; Baska RA; Yang Y; Beyer SM; Monshizadegan H; Dickinson KE; Valentine MT; Humphreys WG; Lan SJ; Ewing WR; Carlson KE; Kowala MC; Zahler R; Macor JE
J Med Chem; 2005 Jan; 48(1):171-9. PubMed ID: 15634011
[TBL] [Abstract][Full Text] [Related]
60. Pleiotropic effects of telmisartan: still more to come?
Benndorf RA; Böger RH
J Hypertens; 2008 May; 26(5):854-6. PubMed ID: 18398324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
